Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01019512 · ClinicalTrials.gov registry record · NA
Flexitouch Lymphedema System in Treating Stage II Lymphedema in Patients With Breast Cancer
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Terminated
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT01019512 is a NA study that was terminated before completion, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 60 participants.
The verdict
NCT01019512, a NA study, was terminated before completion, sponsored by Abramson Cancer Center at Penn Medicine.
- TERMINATED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
RATIONALE: The Flexitouch lymphedema system may lessen lymphedema caused by treatment for breast cancer. It is not yet known whether the Flexitouch lymphedema system is more effective than complex decongestive therapy in treating lymphedema. PURPOSE: This randomized clinical trial is studying the Flexitouch lymphedema system in treating stage II lymphedema in patients with breast cancer.
Interventions
- OTHER questionnaire administration
- OTHER lymphedema management
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2009-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01019512
The ClinicalTrials.gov registry entry for NCT01019512 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which questionnaire administration is the first listed.
NCT01019512 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01019512 about?
NCT01019512 is a clinical study titled "Flexitouch Lymphedema System in Treating Stage II Lymphedema in Patients With Breast Cancer". RATIONALE: The Flexitouch lymphedema system may lessen lymphedema caused by treatment for breast cancer. It is not yet known whether the Flexitouch lymphedema system is more effective than complex decongestive therapy in treating lymphedema. PURPOSE: This randomized clinical trial is studying the Fl...
What is the current status of trial NCT01019512?
This trial is currently terminated. It is a NA study. The enrollment target is 60 participants. The study started on 2009-07.
What interventions are being tested in trial NCT01019512?
The interventions under investigation include: questionnaire administration (OTHER), lymphedema management (OTHER).
Who is sponsoring clinical trial NCT01019512?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.